MCS10XX: lead compound series as complete inhibitors of mast cell activity with high effectivity and safety profile.

MCS20XX: in discovery, selective reduction of accumulated abnormal activated mast cells in controlled dose-dependent manner resulting in a temporary curative approach.

MCS1010: is a derivative of our lead compound as highly effective inhibitor of mast cell activity that contains our discovered pharmacophore acting on activated mast cells, and has a favorable safety profile. MCS1010 is potentially targeted for drug repurposing for new disease indications with urgent high medical needs, and with potential for accelerated approval due to high unmet medical needs.